CSF3 and acute myeloid leukemia: A phase II clinical trial evaluated the immune and clinical outcome of an HLA-A*0201-restricted WT1 epitope peptide vaccine administered with granulocyte colony-stimulating factor (G-CSF) in 17 refractory AML patients [15].